Edition:
India

Interpace Diagnostics Group Inc (IDXG.OQ)

IDXG.OQ on NASDAQ Stock Exchange Capital Market

0.90USD
22 Jun 2018
Change (% chg)

$0.04 (+4.65%)
Prev Close
$0.86
Open
$0.90
Day's High
$0.95
Day's Low
$0.88
Volume
48,318
Avg. Vol
44,212
52-wk High
$1.80
52-wk Low
$0.72

Latest Key Developments (Source: Significant Developments)

Interpace Diagnostics Group Q1 Revenue Rises 39 Percent
Tuesday, 15 May 2018 

May 15 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS, BUSINESS PROGRESS AND RECENT ACCOMPLISHMENTS.Q1 REVENUE ROSE 39 PERCENT TO $4.8 MILLION.QTRLY LOSS PER SHARE $0.11.  Full Article

Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offering​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Interpace Diagnostics Group Inc -:Interpace Diagnostics Group Inc- ‍New York State Department Of Health has reviewed and approved for marketing co's TERT service offering​.  Full Article

Interpace Diagnostics says Q3 sales up 27 pct
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Interpace Diagnostics Group Inc ::Interpace diagnostics group reports third quarter 2017 financial results, business progress and recent accomplishments.Q3 sales rose 27 percent to $4.2 million.Interpace diagnostics group inc qtrly ‍net loss per diluted share of common stock $0.15​.  Full Article

Interpace Diagnostics files for offering of up to $13.8 mln
Monday, 22 May 2017 

May 22 (Reuters) - Interpace Diagnostics Group Inc ::Files for offering of up to $13.8 million .Interpace Diagnostics Group - offering for shares of co's common stock and pre-funded warrants to purchase shares of its common stock.  Full Article

Interpace Diagnostics Group launches multi-site study to provide further evidence of clinical utility of ThyGenx/ThyramiR tests
Tuesday, 13 Dec 2016 

Interpace Diagnostics Group Inc :Interpace Diagnostics Group - has launched multi-site study to provide further evidence of clinical utility of thygenx/thyramir tests.  Full Article

Interpace Diagnostics launches new services for indeterminate thyroid nodules
Thursday, 13 Oct 2016 

Interpace Diagnostics Group Inc : Interpace Diagnostics launches new services for indeterminate thyroid nodules .Interpace Diagnostics Group Inc - expects new service offerings will generate an estimated 400 new specimens in first 45 days following initial launch.  Full Article

Interpace Diagnostics says Nat Krishnamurti to resign as CFO
Friday, 2 Sep 2016 

Interpace Diagnostics Group Inc : On August 29, 2016, Nat Krishnamurti tendered his resignation as CFO, secretary and treasurer of co . On August 29, 2016, company engaged James early as a consultant to serve as interim chief financial officer . Intends to commence a search for a new chief financial officer - SEC filing Source: (http://bit.ly/2bZNBZM) Further company coverage: [IDXG.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Interpace Diagnostics qtrly loss per share $0.13
Tuesday, 16 Aug 2016 

Interpace Diagnostics Group Inc : Q2 revenue rose 60 percent to $3.6 million . Interpace diagnostics reports record revenue and cash collections for the 2016 second quarter . Qtrly loss per share $0.13 .Qtrly loss per share $0.19 from continuing opns.  Full Article

Interpace Diagnostics says NY state approves ThyraMir thyroid test
Friday, 5 Aug 2016 

Interpace Diagnostics Group Inc : Says New York State Department of Health has reviewed and approved ThyraMir . Interpace diagnostics group says it has also filed with new york state seeking approval of ThyGenX, its molecular panel .Interpace diagnostics announces new york state approval of thyroid test.  Full Article

BRIEF-Interpace Diagnostics Enters Agreement With Integrated Health Systems

* INTERPACE DIAGNOSTICS ENTERS AGREEMENT WITH ONE OF THE LARGEST, INTEGRATED HEALTH SYSTEMS IN THE US